Honoured to be speaking at the 34th Singapore Pharmacy Congress 🇸🇬 to share the development journey and translational strategy behind our Callavid® vaginal drug delivery platform.

Calla Lily Clinical Care is focused on advancing a patient centric solution that delivers targeted and user-friendly therapies for conditions with high unmet clinical need. I’ll be sharing our initial use cases, including support for IVF and prevention of threatened miscarriage, along with the broader pipeline potential – spanning hormonal therapies, biotherapeutics, and anti-infectives.

Grateful to Professor Matthias G. Wacker of National University of Singapore and the SPC25 steering committee for the opportunity to join esteemed fellow panellists (Sui Yung Chan, Ayca Altay Benetti, Charles Stacey) working at the forefront of pharmaceutical innovation and women’s health.